In summary, while PARP inhibition is a powerful radiosensitization strategy in lung adenocarcinoma, its success depends on understanding the interconnected roles of senescence, mitochondrial dysfunction, p21 signaling, and underexplored family members such as PARP16. The gene discussed is PARP1; the disease is lung adenocarcinoma.